These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23444969)

  • 1. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study.
    Fiegl M; Steger GG; Studnicka M; Eisterer W; Jaeger C; Willenbacher W
    Curr Med Res Opin; 2013 May; 29(5):505-15. PubMed ID: 23444969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
    Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
    Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
    Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
    Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [OPERa Study].
    Tesařová P
    Klin Onkol; 2013; 26(6):425-33. PubMed ID: 24320592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
    Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
    Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
    Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
    J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
    Freyer G; Kalinka-Warzocha E; Syrigos K; Marinca M; Tonini G; Ng SL; Wong ZW; Salar A; Steger G; Abdelsalam M; DeCosta L; Szabo Z
    Med Oncol; 2015 Oct; 32(10):236. PubMed ID: 26315712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.
    Weycker D; Li X; Barron R; Li Y; Reiner M; Kartashov A; Figueredo J; Tzivelekis S; Garcia J
    Support Care Cancer; 2016 Jun; 24(6):2481-90. PubMed ID: 26670915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
    Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutropenia-associated outcomes in adults with acute myeloid leukemia receiving cytarabine consolidation chemotherapy with or without granulocyte colony-stimulating factor.
    Bradley AM; Deal AM; Buie LW; van Deventer H
    Pharmacotherapy; 2012 Dec; 32(12):1070-7. PubMed ID: 23208834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.